Glonghui, May 3, 丨 Minimally Invasive Robot-B (2252.HK) opened more than 10% higher at HK$31.35, with a total market value of HK$30.1 billion. Minimally invasive robots announced yesterday that the company and Biobot Cooperate Pte. Ltd., the product of the Mona Lisa Prostate Piercing Robot Positioning System (“Mona Lisa”) belonging to Shanghai Jiaihang Robotics Co., Ltd., a joint venture established in China, has completed all registered clinical trials. The registered clinical trial was led by Gulou Hospital affiliated to Nanjing University School of Medicine, and the First Affiliated Hospital of Xi'an Jiaotong University and the Northern Jiangsu People's Hospital participated in the research. Mona Lisa runs stably during surgery, is safe to operate, and has a smooth process. It has obvious advantages over traditional surgical manual puncture methods in terms of surgical safety, learning curve, and puncture detection rate, and has great clinical value.